<<Back
Chembio Diagnostics and Takeda Pharmaceutical Complete Feasibility Study
Chembio originally announced in
“We are pleased to complete the feasibility phase, which demonstrates once again the diverse applications of Chembio’s novel technologies,” said
“This program uses the second generation of Chembio’s analyzer, which was developed and achieved CE-mark during 2019 by our team in
Chembio’s DPP platform is the same technology used for the company’s DPP HIV 1/2 Assay, which has achieved numerous global regulatory approvals, including FDA-approval, CLIA-waiver, WHO prequalification, CE mark, and ANVISA approval.
About
Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases. The company’s patented DPP technology platform, which uses a small drop of blood from the fingertip, provides high-quality, cost-effective results in approximately 15 minutes. Coupled with Chembio’s extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease, a number of which applications are under active development with collaboration partners. Chembio’s products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Learn more at www.chembio.com.
DPP is Chembio’s registered trademark. For convenience, this trademark appears in this release without ® symbols, but that practice does not mean that Chembio will not assert, to the fullest extent under applicable law, its rights to the trademark.
Investor contact:
(415) 937-5406
investor@chembio.com
Source: Chembio Diagnostics, Inc.